Rational combinations of siRNAs targeting Plk1 with breast cancer drugs (Q79976833)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17369857%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

title

Rational combinations of siRNAs targeting Plk1 with breast cancer drugs (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17369857%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference

B Spänkuch

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17369857%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

E Kurunci-Csacsko

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17369857%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

M Kaufmann

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17369857%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

K Strebhardt

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17369857%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

publication date

19 March 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17369857%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17369857%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17369857%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

issue

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17369857%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

page(s)

5793-5807

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17369857%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.onc.1210355

27 December 2019

exact match

0 references

cites work

Polo-like kinase (Plk) 1: a novel target for the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

Polo-like kinases and the orchestration of cell division

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

p27 as a target for cancer therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

A multistep model for paclitaxel-induced apoptosis in human breast cancer cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

1 reference

7 January 2021

Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

A potential synergistic anticancer effect of paclitaxel and amifostine on endometrial cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

HER2 signaling downregulation by trastuzumab and suppression of the PI3K/Akt pathway: an unexpected effect on TRAIL-induced apoptosis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

Polo-like kinases and oncogenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

Antisense therapy for cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

Microtubules as a target for anticancer drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

The polo-like protein kinases Fnk and Snk associate with a Ca(2+)- and integrin-binding protein and are regulated dynamically with synaptic plasticity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

Normal cells, but not cancer cells, survive severe Plk1 depletion

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

HER2 therapy: molecular mechanisms of trastuzumab resistance.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

Herceptin: mechanisms of action and resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

Taxol stabilizes microtubules in mouse fibroblast cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

Polo-like kinase-1 is a target of the DNA damage checkpoint

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

RNA interference-based gene silencing in mice: the development of a novel therapeutical strategy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

Targeting polo-like kinase 1 for cancer therapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

Cationic liposome-mediated gene delivery in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

Measuring the clinical response. What does it mean?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021

RNAi-mediated gene silencing in non-human primates.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210355

7 January 2021